Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 5,342 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Normal Saline Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients

NCT01501929
View directory record Official record
Conditions
Hypertension
Interventions
Metoprolol succinate, Nebivolol, Non-invasive measurement of Cardiac Output (CO), Endothelial cell collection, Microvascular perfusion assessment using Definity
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Oct 18, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy Subjects

NCT02508753
View directory record Official record
Conditions
Healthy
Interventions
CXA-101/tazobactam, Moxifloxacin, placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 18, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

Contrast-enhanced Ultrasound Evaluation of Chemoembolization

NCT02764801
View directory record Official record
Conditions
Hepatocellular Carcinoma, Chemoembolization, Therapeutic
Interventions
Ultrasound contrast agent (Contrast-enhanced ultrasound), Logiq E9 Scanner (Contrast-enhanced ultrasound)
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
21 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
La Jolla, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 18, 2026, 5:57 AM EDT
Recruiting Phase 3 Interventional

PRP in ACLR to Prevent PTOA

NCT05412381
View directory record Official record
Conditions
Anterior Cruciate Ligament Injuries, Post-traumatic Osteoarthritis, PRP
Interventions
platelet rich plasma (PRP) injection, placebo saline injection
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
14 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 18, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

Intranasal Insulin and Post-stroke Cognition: A Pilot Study

NCT02810392
View directory record Official record
Conditions
Stroke
Interventions
Intranasal Insulin, Intranasal saline
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 18, 2026, 5:57 AM EDT
Terminated Phase 3 Interventional Results available

IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy

NCT02697292
View directory record Official record
Conditions
Autoimmune Epilepsy
Interventions
Intravenous Immunoglobulin, Placebos, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Oct 18, 2026, 5:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacoeconomics and Related Patient Outcomes of Multi-dose Intravenous Acetaminophen (OFIRMEV)

NCT02369211
View directory record Official record
Conditions
Prostatectomy, Pain
Interventions
Acetaminophen (Ofirmev), Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years · Male only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 18, 2026, 5:57 AM EDT
Completed Phase 2 Interventional

Study of HGF Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia

NCT00060892
View directory record Official record
Conditions
Arterial Occlusive Disease, Peripheral Vascular Disease, Ischemia
Interventions
HGF plasmid
Genetic
Lead sponsor
AnGes USA, Inc.
Industry
Eligibility
40 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2008 · Synced Oct 18, 2026, 5:57 AM EDT
Terminated Phase 2 Interventional Results available

Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma

NCT01727336
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma
Interventions
Dalantercept and axitinib, Placebo and axitinib
Drug
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
36
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 18, 2026, 5:57 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age

NCT05127434
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Placebo, mRNA-1345
Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
60 Years and older
Enrollment
36,814 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
133
States / cities
Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 114 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 18, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Results available

A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT01254409
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
PRM-151, Placebo
Biological · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 18, 2026, 5:57 AM EDT
Completed Phase 4 Interventional Results available

Topical (Intra-Articular) Tranexamic Acid and Transfusion Rates Following Hip Hemiarthroplasty

NCT02664909
View directory record Official record
Conditions
Femoral Neck Fractures
Interventions
Tranexamic Acid, Placebo (saline)
Drug
Lead sponsor
UConn Health
Other
Eligibility
55 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Farmington, Connecticut • Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 18, 2026, 5:57 AM EDT
Withdrawn Not applicable Interventional

Transcranial Direct Current Stimulation and Cognitive Remediation Therapy for Interictal Dysfunction in Epilepsy

NCT02950506
View directory record Official record
Conditions
Epilepsy
Interventions
transcranial direct current stimulation, Cognitive Remediation Therapy
Device · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 18, 2026, 5:57 AM EDT
Completed Phase 4 Interventional Results available

Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)

NCT02589600
View directory record Official record
Conditions
Osteoporotic Fractures, Osteoporosis, Postmenopausal
Interventions
Zoledronic acid, vitamin D, calcium, Saline
Drug · Dietary Supplement · Other
Lead sponsor
Susan L. Greenspan
Other
Eligibility
65 Years and older · Female only
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New Kensington, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 18, 2026, 5:57 AM EDT
Completed Phase 3 Interventional

Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)

NCT03617367
View directory record Official record
Conditions
Cervical Dystonia
Interventions
daxibotulinumtoxinA for injection
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
37
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 18, 2026, 5:57 AM EDT
Terminated Phase 3 Interventional Results available

Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer

NCT04163900
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
NUC-1031, Gemcitabine, Cisplatin
Drug
Lead sponsor
NuCana plc
Other
Eligibility
18 Years and older
Enrollment
773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
29
States / cities
Tucson, Arizona • Whittier, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 18, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Exenatide for Smoking Cessation and Prevention of Weight Gain

NCT05610800
View directory record Official record
Conditions
Smoking Cessation, Weight Gain
Interventions
Exenatide 2 milligram (mg) Injection, Placebo, Nicotine patch, Smoking Cessation Counseling
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 18, 2026, 5:57 AM EDT
Completed Not applicable Interventional Results available

Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies

NCT01949844
View directory record Official record
Conditions
Coronary Artery Disease, CAD
Interventions
regadenoson, Optimark®, Myocardial perfusion MRI
Drug · Device
Lead sponsor
Daniel S. Berman
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 18, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

NCT06097299
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
47
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Banning, California + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 18, 2026, 5:57 AM EDT
Completed Phase 4 Interventional Results available

Comparing Post-Op Narcotic Usage in Patients Receiving Periarticular Exparel vs. Standard Periarticular Joint Inj

NCT02682498
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee
Interventions
(Bupivacaine Liposome Injectable Suspension), Standard Preparation
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 18, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE

NCT03312907
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab, Rituximab, Rituximab-placebo, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
28
States / cities
Birmingham, Alabama • La Mesa, California • San Leandro, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 18, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DCVax Plus Poly ICLC in Healthy Volunteers

NCT01127464
View directory record Official record
Conditions
HIV-1 Infection, HIV Infection, Healthy Volunteers
Interventions
DCVax-001, Poly-ICLC, Placebo
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Oct 18, 2026, 5:57 AM EDT
Completed No phase listed Observational

Evaluation of the Lungs of Individuals With Lung Disease

NCT00224198
View directory record Official record
Conditions
Lung Disease, Bronchitis, Emphysema, COPD, Asthma
Interventions
Lung Disease
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 18, 2026, 5:57 AM EDT
Active, not recruiting Phase 3 Interventional

Trial to Assess Chelation Therapy in Critical Limb Ischemia

NCT03982693
View directory record Official record
Conditions
Critical Limb Ischemia, Diabetes
Interventions
Edetate Disodium, Placebo
Drug · Other
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 18, 2026, 5:57 AM EDT